Osborne CK - Search Results

1

Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.

Albain KS, Green S, LeBlanc M, Rivkin S, O'Sullivan J, Osborne CK. Albain KS, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1992;22(3):273-84. doi: 10.1007/BF01840840. Breast Cancer Res Treat. 1992. PMID: 1391993

2

Chemotherapy versus observation in high-risk node-negative breast cancer patients.

Mansour EG, Eudey L, Tormey DC, Shatila AH, Osborne CK, Gilchrist KW, Cooper MR, Falkson G. Mansour EG, et al. Among authors: osborne ck. J Natl Cancer Inst Monogr. 1992;(11):97-104. J Natl Cancer Inst Monogr. 1992. PMID: 1627437 Clinical Trial.

3

A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer.

Budd GT, Green S, Baker LH, Hersh EP, Weick JK, Osborne CK. Budd GT, et al. Among authors: osborne ck. Cancer. 1991 Oct 15;68(8):1694-5. doi: 10.1002/1097-0142(19911015)68:8<1694::aid-cncr2820680806>3.0.co;2-k. Cancer. 1991. PMID: 1913510 Clinical Trial.

4

Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.

Von Hoff DD, Green SJ, Neidhart JA, Fabian C, Budd T, Boyd JF, Osborne CK. Von Hoff DD, et al. Among authors: osborne ck. Invest New Drugs. 1991 Feb;9(1):87-8. doi: 10.1007/BF00194553. Invest New Drugs. 1991. PMID: 2026487 Clinical Trial. No abstract available.

5

Adjuvant therapy in node-negative breast cancer. A panel discussion.

McGuire WL, Abeloff MD, Fisher B, Glick JH, Henderson IC, Osborne CK. McGuire WL, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1989 Mar;13(2):97-115. doi: 10.1007/BF01806522. Breast Cancer Res Treat. 1989. PMID: 2659105 Clinical Trial. No abstract available.

6

Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.

Rivkin SE, Green S, Metch B, Glucksberg H, Gad-el-Mawla N, Constanzi JJ, Hoogstraten B, Athens J, Maloney T, Osborne CK, et al. Rivkin SE, et al. Among authors: osborne ck. J Clin Oncol. 1989 Sep;7(9):1229-38. doi: 10.1200/JCO.1989.7.9.1229. J Clin Oncol. 1989. PMID: 2671283 Clinical Trial.

7

Adjuvant therapy of breast cancer: Southwest Oncology Group studies.

Osborne CK, Rivkin SE, McDivitt RW, Green S, Stephens RL, Costanzi JJ, O'Bryan R. Osborne CK, et al. NCI Monogr. 1986;(1):71-4. NCI Monogr. 1986. PMID: 3534592 Clinical Trial.

8

Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM.

Rivkin SE, Glucksberg H, Foulkes M, Osborne CK, Tranum W, Gad-el-Mawla N, Constanzi J. Rivkin SE, et al. Among authors: osborne ck. World J Surg. 1985 Oct;9(5):719-22. doi: 10.1007/BF01655186. World J Surg. 1985. PMID: 3840628 Clinical Trial. No abstract available.

9

Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.

Rivkin SE, Knight WA 3rd, McDivitt R, Cruz T, Foulkes M, Osborne CK, Fabian CJ, Costanzi JJ. Rivkin SE, et al. Among authors: osborne ck. World J Surg. 1985 Oct;9(5):723-7. doi: 10.1007/BF01655187. World J Surg. 1985. PMID: 3840629 Clinical Trial. No abstract available.

10

Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.

Rivkin SE, Knight WA 3rd, McDivitt R, Cruz T, Foulkes M, Osborne CK, Fabian CJ, Costanzi JJ. Rivkin SE, et al. Among authors: osborne ck. J Steroid Biochem. 1985 Dec;23(6B):1151-4. doi: 10.1016/0022-4731(85)90035-4. J Steroid Biochem. 1985. PMID: 3912621 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

375 results

Search Page

Filters